StockData

Cerenome vs Lucid Diagnostics

CNSY and LUCD side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CNSY and LUCD compare

Lucid Diagnostics is the larger company, worth 17 times as much as Cerenome ($81.1M against $4.8M).

Lucid Diagnostics grew revenue faster over the last twelve months (24.9% versus −21.0% for Cerenome).

Cerenome keeps more of each dollar of sales as profit, with a net margin of −621% compared with −960% at Lucid Diagnostics.

Cerenome scores higher on the StockData Score (8 against 7 for Lucid Diagnostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCNSYLUCD
Size and price
Market cap$4.8M$81.1M
Share price$0.630$0.399
Change, 1 year−95.1%−62.7%
Change, 5 years−98.3%−95.3%
Beta (5Y)4.921.89
Employees2882
StockData Score
Total score8 (better)7
Valuation score3 (better)0
Growth score12 (better)
Performance score01 (better)
Health score44
Dividend score00
Valuation
P/S1.1× (better)14.9×
P/B0.9× (better)7.4×
FCF yield−492%–
Fair value$2.14$0.298
Margin of safety70.5% (better)−33.9%
Growth
Revenue growth (TTM)−21.0%24.9% (better)
Profitability
Operating margin−628% (better)−931%
Net margin−621% (better)−960%
FCF margin−560%–
Return on equity−614%−556% (better)
Financial health
Debt / equity0.000.00
Interest coverage−1200.0× (better)−2815.8×
Current ratio1.37 (better)1.33
Altman Z-score−58.37−13.38 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions8.3%30.2%
Held by insiders4.2%24.8%
Insider net buying, 12 months$0$245K (better)
Short interest, % of float11.6%9.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.